There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .
Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial.
The physiological role of dehydroepi and rosterone ( DHEA ) is not well understood , but studies suggest positive effects on subjective health and bone metabolism . We have conducted a clinical trial with DHEA replacement in adrenal failure with the primary aim of evaluating effects on subjective health status and sexuality .  Thirty-nine women with adrenal failure were r and omized to 9 months of treatment with 25 mg DHEA ( n = 19 ) or placebo ( n = 20 ) . Treatment effects were assessed by vali date d question naires of subjective health and sexuality .  DHEA replacement yielded a wide variation of effects on the subjective health scales , which were not different from the effects of placebo . Almost all patients receiving DHEA obtained normal and rogen levels . Eighty-nine percent of the patients receiving DHEA experienced side-effects , in particular increased sweat odor and scalp itching .  DHEA replacement did not significantly change the levels of blood lipids , IGF-I , and markers of bone metabolism . In conclusion , we do not find evidence of beneficial effects of DHEA on subjective health status and sexuality in adrenal failure . However , DHEA may be beneficial for subgroups of patients with adrenal failure , but these remain to be identified . Premenopausal and rogen levels can be restored with 25 mg DHEA daily in most female patients , but side-effects are frequent
There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .